KA
GILD icon

Kozak & Associates’s Gilead Sciences GILD Stock Holding History

Kozak & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Hold
3,000
– – 0.07% 56
2026
Q1 		$417K Hold
3,000
– – 0.08% 47
2025
Q4 		$363K Hold
3,000
– – 0.07% 51
2025
Q3 		$372K Sell
3,000
-19
-0.6% -$2.16K 0.07% 59
2025
Q2 		$342K Buy
3,019
+2,969
+5,938% +$316K 0.07% 57
2025
Q1 		$5.34K Hold
50
– – ﹤0.01% 285
2024
Q4 		$4.57K Buy
+50
New +$4.5K ﹤0.01% 299

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kozak & Associates's GILD Position: Q2 2026 in Review

Kozak & Associates held its Gilead Sciences (GILD) position steady in Q2 2026 at 3,000 shares worth $378K. The position accounts for 0.07% of the portfolio, ranked #56.

Kozak & Associates first reported a position in GILD in Q4 2024 and has held it in 7 quarters since. The position peaked at $417K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Kozak & Associates held 3,000 shares of Gilead Sciences worth $378K as of Q2 2026.
  • Kozak & Associates left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.07% of Kozak & Associates's portfolio in Q2 2026, its #56 holding.
  • Kozak & Associates first reported a position in Gilead Sciences in Q4 2024 and has held it in 7 quarters since.
  • Kozak & Associates's Gilead Sciences position peaked at $417K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Kozak & Associates's 13F filing for Q2 2026, filed 2 Jul 2026.